Differentiation therapy: Targeting human renal cancer stem cells with interleukin 15

Journal of the National Cancer Institute

Volumn 103, Issue 24, 2010, Pages 1884-1898

  Azzi, Sandy ^a   Bruno, Stefania ^b   Giron Michel, Julien ^a   Clay, Denis ^a   Devocelle, Aurore ^a   Croce, Michela ^c   Ferrini, Silvano ^c   Chouaib, Salem ^d   Vazquez, Aimé ^a   Charpentier, Bernard ^a   Camussi, Giovanni ^b   Azzarone, Bruno ^a   Eid, Pierre ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ENDOGLIN; PACLITAXEL; RECOMBINANT INTERLEUKIN 15; VINBLASTINE; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; INTERLEUKIN 15; LEUKOCYTE ANTIGEN; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CANCER; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; STEM CELL TRANSPLANTATION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOUSE MUTANT; RECURRENT DISEASE; TUMOR RECURRENCE; XENOGRAFT;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-15; KIDNEY NEOPLASMS; MICE; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RECEPTORS, CELL SURFACE; RECURRENCE; STAT5 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84855859957     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr451     Document Type: Article

References (48)

1. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-5828. (Pubitemid 37187480)
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-3988. (Pubitemid 36418143)
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737. (Pubitemid 27298715)
4. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111- 115. (Pubitemid 46067311)
5. Hermann PC, Bhaskar S, Cioffi M, et al. Cancer stem cells in solid tumors. Semin Cancer Biol. 2010;20(2):77-84.
6. Bussolati B, Bruno S, Grange C, et al. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008;22(10):3696-3705.
7. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506-5511. (Pubitemid 40911148)
8. Keysar SB, Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther. 2010;9(9):2450-2457.
9. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8(10):806-823.
10. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007;21(14):3777-3785. (Pubitemid 350232335)
11. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol. 2006;17(11):1620-1624. (Pubitemid 44680880)
12. Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol. 2005;15(5):289-297. (Pubitemid 41242247)
13. Budagian V, Bulanova E, Paus R, et al. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17(4):259-280. (Pubitemid 44038618)
14. Huang YS, Cheng SN, Chueh SH, et al. Effects of interleukin-15 on neuronal differentiation of neural stem cells. Brain Res. 2009;1304(1):38-48.
15. Shinozaki M, Hirahashi J, Lebedeva T, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest. 2002;109(7):951-960. (Pubitemid 34275116)
16. Lamana A, Ortiz AM, Alvaro-Gracia JM, et al. Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw. 2010;21(3):186-194.
17. Lewis E, Weiler M, Chaimovitz C, et al. Interleukin-15 is the main mediator of lymphocyte proliferation in cultures mixed with human kidney tubular epithelial cells. Transplantation. 2001;72(5):886-890. (Pubitemid 32879863)
18. Khawam K, Giron-Michel J, Gu Y, et al. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res. 2009;69(4):1561-1569.
19. Giron-Michel J, Menard F, Negrini S, et al. EBV-associated mononucleosis does not induce long-term global deficit in T-cell responsiveness to IL-15. Blood. 2009;113(19):4541-4547.
20. Kobayashi I, Moritomo T, Ototake M, et al. Isolation of side population cells from ginbuna carp (Carassius auratus langsdorfii) kidney hematopoi-etic tissues. Dev Comp Immunol. 2007;31(7):696-707. (Pubitemid 46507602)
21. Sonoda S, Spee C, Barron E, et al. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nat Protoc. 2009;4(5):662-673.
22. Tejman-Yarden N, Zlotnik M, Lewis E, et al. Renal cells express a functional interleukin-15 receptor. Nephrol Dial Transplant. 2005;20(3):516-523. (Pubitemid 40378419)
23. Loh YH, Wu Q, Chew JL, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38(4):431-440.
24. Yang XH, Wu QL, Yu XB, et al. Nestin expression in different tumours and its relevance to malignant grade. J Clin Pathol. 2008;61(4):467-473. (Pubitemid 351518229)
25. Trinder P, Seitzer U, Gerdes J, et al. Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. Int J Oncol. 1999;14(1):23-31.
26. Chin JH, Shiwaku H, Goda O, et al. Neural stem cells express Oct-3/4. Biochem Biophys Res Commun. 2009;388(2):247-251.
27. Musch MW, Walsh-Reitz MM, Chang EB. Roles of ZO-1, occludin, and actin in oxidant-induced barrier disruption. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G222-G231.
28. Grone HJ, Weber K, Helmchen U, et al. Villin-a marker of brush border differentiation and cellular origin in human renal cell carcinoma. Am J Pathol. 1986;124(2):294-302. (Pubitemid 16016646)
29. Alison MR, Guppy NJ, Lim SM, et al. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol. 2010;222(4):335-344.
30. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101(39):14228-14233. (Pubitemid 39305058)
31. Wang YH, Li F, Luo B, et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma. 2009;56(5):371-378.
32. Larkin JM, Chowdhury S, Gore ME. Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol. 2007;4(8):470-479. (Pubitemid 47393803)
33. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43(5):935-946. (Pubitemid 46366698)
34. Morrison BJ, Schmidt CW, Lakhani SR, et al. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res. 2008;10(4):210.
35. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946-10951. (Pubitemid 41713363)
36. McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 2010;28(26):4022-4028.
37. Eini H, Tejman-Yarden N, Lewis EC, et al. Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury. J Interferon Cytokine Res. 2010;30(1):1-8.
38. Eckardt KU, Bernhardt W, Willam C, et al. Hypoxia-inducible transcription factors and their role in renal disease. Semin Nephrol. 2007;27(3):363-372. (Pubitemid 46802919)
39. Srivastava VK, Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry A. 2008;73(10):940-948.
40. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595-601. (Pubitemid 44134092)
41. Arina A, Murillo O, Dubrot J, et al. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Ther. 2008;15(7):473-483. (Pubitemid 351405087)
42. Meazza R, Lollini PL, Nanni P, et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, met-astatic potential and immune response. Int J Cancer. 2000;87(4):574-581. (Pubitemid 30639819)
43. Munger W, DeJoy SQ, Jeyaseelan R Sr, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol. 1995;165(2):289-293.
44. Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011;117(18):4787-4795.
45. Ogris M, Wagner E. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? Hum Gene Ther. 2011;22(7):799-807.
46. Munz C, Dao T, Ferlazzo G, et al. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005;105(1):266-273. (Pubitemid 40053092)
47. Senju S, Matsunaga Y, Fukushima S, et al. Immunotherapy with pluripotent stem cell-derived dendritic cells [published online ahead of print April 5, 2011]. Semin Immunopathol. 2011.
48. Soleimani A, Berntsen A, Svane IM, et al. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009;70(5):481-489.